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Abstract
Background: Over-expression and increased activity of cyclooxygenase (COX)-2 induced by smoking has been implicated in
the development of cancer. This study aimed to explore the interaction between smoking and functional polymorphisms of
COX-2 in modulation of gastric cardia adenocarcinoma (GCA) risk.
Methods and Findings: Three COX-2 polymorphisms, including –1195G.A (rs689466), –765G.C (rs20417), and
587Gly.Arg (rs3218625), were genotyped in 357 GCA patients and 985 controls. In the multivariate logistic regression
analysis, we found that the –1195AA, –765GC, and 587Arg/Arg genotypes were associated with increased risk of GCA
(OR=1.50, 95% CI=1.05–2.13; OR=2.06, 95% CI=1.29–3.29 and OR=1.67, 95% CI=1.04–2.66, respectively). Haplotype
association analysis showed that compared with G21195-G2765-G Gly587Arg, the A21195-C2765-AGly587Arg conferred an
increased risk of GCA (OR=2.49, 95% CI=1.54–4.01). Moreover, significant multiplicative interactions were observed
between smoking and these three polymorphisms of –1195G.A, –765G.C, and 587Gly.Arg, even after correction by false
discovery rate (FDR) method for multiple comparisons (FDR-Pinteraction=0.006, 5.239610
24 and 0.017, respectively). Similarly,
haplotypes incorporating these three polymorphisms also showed significant interaction with smoking in the development
of GCA (P for multiplicative interaction=2.65610
26).
Conclusion: These findings indicated that the functional polymorphisms of COX-2, in interaction with smoking, may play a
substantial role in the development of GCA.
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Introduction
Gastric cardia adenocarcinoma (GCA) is the second leading
cause of cancer-related mortality in the world, with more than
700,000 deaths annually [1,2,3]. In China, GCA is also one of
prevalent fatal malignancies. During the past two decades,
epidemiological studies have shown a steady decline in incidence
of non-cardia gastric cancer but a continuously increased trend in
incidence and mortality of GCA, thus emphasizing the importance
of prevention strategy to GCA [4,5]. Extensive studies have
revealed several environmental factors involved in the develop-
ment of GCA, including cigarette smoking, alcohol consumption,
inflammation, and diet. Most significantly, smoking has been
established by considerable studies as a causal factor for GCA [6],
which was supported by a recent meta-analysis including 33
studies that smokers had 1.8 fold increased risk of GCA than
never-smokers [7]. However, the underlying mechanism how
smoking promotes GCA development remains to be fully eluci-
dated. Recently, cumulative evidence has shown that smoking
contributed to carcinogenesis potentially through induction of
COX-2 and its downstream metabolites [8].
Cyclooxygenase-2 (COX-2), a key enzyme converting arachi-
donate to prostaglandins, was absent from normal cells unless
rapidly induced by various carcinogens. For instance, the tobacco
specified carcinogen, nicotine, has been shown to up-regulate
COX-2 expression and activity in vitro and in vivo [9]. Moreover, in
nicotine treated hamsters, COX-2 was significantly increased in
gastrointestinal cancer [10,11,12]. Interestingly, in the gastric
cancer cells with nicotine-induced COX-2-derived PGE2 release
and cell proliferation, the COX-2 inhibitor SC-236 caused G1
arrest and abrogated nicotine-induced cell proliferation [13]. It is
therefore concluded that COX-2 played key role in smoke-
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activity of COX-2 induced by smoking may vary among
individuals, and only small fraction of exposure individuals would
develop to GCA during their life spans, suggesting genetic
mechanism depending on COX-2 might be involved in suscept-
ibility to smoke-associated GCA [14,15].
Intriguingly, by direct sequencing and biochemical assays, we
have previously identified three functional single nucleotide
polymorphisms (SNPs) in COX-2 gene, including –1195 G.A
(rs689466) and –765G.C (rs20417) in promoter region and
587Gly.Arg (1759G.A, rs3218625) in coding region, of which,
the G to A variant in –1195 locus created a c-myeloblastosis
oncogene (c-MYB) binding site, resulting in higher transcriptional
activity of COX-2 [16]. The –765C allele might attribute to
heighten smoking-induced expression of COX-2 by creating a
binding site for phosphorylated NPM (P-NPM), which acted as a
specific transcriptional inhibitor and was driven to cytoplasm once
with smoking stimulation [17]. In addition, the 587Gly.Arg
variant was associated with the enhanced activity of COX-2 in vitro
by causing the Gly to Aly amino acid substitution in codon 587 of
exon10 [18]. Therefore, an alternative hypothesis was motivated
by solid biological plausibility that these three functional SNPs
might interact with smoking to modulate the GCA risk. To test
this hypothesis, –1195 G.A (rs689466), –765G.C (rs20417), and
587Gly.Arg (rs3218625) were analyzed in a case-control study
consisting of 357 GCA cases and 985 controls in a Chinese Han
population, and the interaction between these three SNPs and
smoking exposure was investigated in modulation of GCA risk.
Materials and Methods
Study subjects
This study consisted of 357 GCA patients and 985 controls. All
subjects were unrelated Han Chinese from Beijing city and its
surrounding region. Patients were recruited between July 1999
and July 2005 at the Peking Union Hospital and Cancer Hospital,
Chinese Academy of Medical Sciences (Beijing). The inclusion
criteria for patients included histopathologically confirmed GCA,
without previous chemotherapy or radiotherapy, and no restric-
tion in regards to sex, age, or disease stage. The controls were
cancer-free individuals randomly selected from a pool of 3000
normal individuals in the Beijing area during the same period. The
selection criteria for controls included cancer-free individuals and
frequency matching to cases by sex and age (65 years). At
recruitment, written informed consent was obtained from each
subject, and the information on demographic characteristics, such
as sex, age, and smoking status were collected via questionnaire.
Subjects who had never smoked or smoked less than 1 cigarette
per day and shorter than 1 year were defined as non-smokers;
otherwise, they were considered as smokers (including current
smokers and ex-smokers). This study was approved by the
institutional review boards of the Chinese Academy of Medical
Sciences Cancer Institute and Tongji Medical College of
Huazhong University of Science and Technology.
COX-2 genotyping
Genomic DNA was extracted from whole blood samples of all
subjects. Genotypes of three SNPs (including COX-2 –1195G.A,
–765G.C, and 587 Gly.Arg) were determined by polymerase
chain reaction (PCR)-based restriction fragment length poly-
morphism (RFLP) methods as described previously [16]. Geno-
typing was performed without knowledge of the case or control
status of the subjects. Genotypes determined by RFLP were
further confirmed by direct sequencing in 30 random DNA
samples, with the 100% concurrence rate of these two methods.
Additionally, a 15% masked, random sample from cases and
controls was tested twice by different investigators, and the results
were concordant for all of the duplicate sets.
Statistical analysis
x
2 test was used to compared the distribution of demographic
characteristics between cases and controls. Hardy-Weinberg
equilibrium for genotypes was tested by a goodness-of-fit x
2 test
in control group. Multivariate logistic regression was used to
evaluate the associations between GCA risk and smoking, COX-2
genotypes or haplotypes. The interaction between smoking and
COX-2 SNPs were estimated via multiplicative interaction term
and the stratified analysis of the effect of SNPs on GCA by
smoking status. A two-tailed P,0.05 was used as the criterion of
statistical significance. The final P values were adjusted by the false
discovery rate (FDR) correction for multiple comparisons [19]. All
statistical analyses were conducted by SPSS v13.0 software.
Linkage disequilibrium (LD) of these three SNPs was analyzed
using Haploview v4.0 [20]. Haplotypes composing these three
SNPs were estimated using Phase v2.1 [21].
Results
Subjects characteristics
The demographic characteristics of all subjects are presented in
Table 1. The cases and controls were matched well on sex and age
distribution. There were 53.7% smokers among cases compared
with 45% among controls. Significant difference in smoking status
was observed between case and control groups (P=0.006). In the
logistic regression model, smokers had an increased risk of GCA
compared with non-smokers after adjusting for sex and age
(OR=1.41, 95% CI=1.08–1.84).
COX-2 genotypes and GCA risk
The genotype distributions of the COX-2 –1195G.A, –
765G.C, and 587 Gly.Arg are shown in Table 2. All the
genotypes of these three SNPs in controls conformed to Hardy-
Weinberg equilibrium (P=0.056, 0.463, and 0.394, respectively).
For the –765G.C and 587 Gly.Arg polymorphsims, no variant
homozygotes were observed in this study population. Frequencies
for the variant alleles of 21195A, 2765C, and 587Arg were 0.56,
Table 1. Distributions of select characteristics among cases
and controls.
Variable
Controls (n = 985)
N( % )
Cases (n = 357)
N( % ) P value
Gender 0.103
Male 810 (82.2) 307 (86.0)
Female 175 (17.8) 50 (14.0)
Age 0.453
#45 102 (10.4) 29 (8.1)
46–55 214 (21.7) 76 (21.3)
56–65 380 (38.6) 134 (37.5)
.65 289 (293) 118 (33.1)
Smoking status 0.006
Nonsmoker 542 (55.0) 166 (46.5)
Smoker 443 (45.0) 191 (53.5)
doi:10.1371/journal.pone.0021894.t001
COX-2 SNPs and Gastric Cardia Adenocarcinoma
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e218940.09, and 0.08 in cases and 0.51, 0.05, 0.05 in controls,
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In the logistic regression analysis, after adjusting for age, sex,
and smoking status, individuals with the 21195AA genotype
presented an elevated risk of GCA compared with those with the
21195GG genotype (OR=1.50, 95% CI=1.05–2.13). For the –
765G/C SNP, individuals with the –765GC genotype had more
than 2-fold increased risk of GCA (OR=2.06, 95% CI=1.29–
3.29) compared with carriers of the –765GG genotype. Similarly,
the 587Gly/Arg genotype also conferred 1.67 fold increased risk
compared with the Gly/Gly genotype (95% CI=1.04–2.66).
Moreover, the effect of the 21195GG, –765GC, or 587Gly/Arg
genotype achieved the significant level after correction by FDR for
multiple comparisons (FDR-P=0.038, 0.009, and 0.033).
COX-2 haplotypes and GCA risk
LD analysis showed that these three SNPs are not in discernible
linkage disequilibrium in this study population (Table S1). As
shown in Table 3, five common haplotypes composing these three
SNPs were observed in this study population, of which, the
A21195-G2765-GGly587Arg haplotype was the most prevalent
haplotype both in cases and controls (48.7% and 50.6%,
respectively). Treating the G21195-G2765-GGly587Arg haplotype as
reference, the haplotype A21195-C2765-GGly587Arg showed the
significantly highest risk of GCA compare with other haplotypes
(OR=2.49, 95% CI=1.54–4.01), and the G21195-G2765-
AGly587Arg was also significantly associated with the increased
GCA risk (OR=1.71, 95% CI=1.01–2.88). Moreover, a
significant allele-dose effect of haplotypes was observed in
increasing risk of GCA (P for trend=1.000610
-5).
Interaction of COX-2 genotypes and smoking
In this current study, we evaluated the interaction of these three
SNPs and smoking by stratified analysis and the multiplicative
interaction term (Table 4). In the stratified analysis, none of the –
1195G.A, –765G.C and 587Gly.Arg variants were associated
with risk of GCA among nonsmokers, whereas smokers with the –
1195GA+AA, –765GC or 587 Gly/Arg genotype all showed
increased risk of GCA compared with non-smokers carrying the
wild-type genotypes (OR=1.64, 95% CI=1.0622.53;
OR=3.98, 95% CI=2.0627.69 and OR=2.67, 95%
CI=1.3625.23, respectively). Moreover, significantly multiplica-
tive interaction were observed between these three COX-2 SNPs
and smoking, even after correction by FDR for multiple
comparisons (FDR-Pinteraction=0.006, 5.239610
-4, 0.017).
Interaction of COX-2 haplotypes and smoking
We further explored the interaction of COX-2 haplotypes and
smoking in GCA (Table 5). Defining nonsmokers with the G21195-
G2765-GGly587Arg haplotype as the reference group, no significant
association was observed between any haplotype and GCA risk
among non-smokers, whereas smokes with the haplotype of
G21195-G2765-GGly587Arg,A 21195-G2765-GGly587Arg,G 21195-
G2765-AGly587Arg,A 21195-C2765-GGly587Arg,o rA 21195-G2765-
AGly587Arg all showed elevated risk for developing GCA
(OR=1.38, 95% CI=1.05–1.82; OR=1.62, 95% CI=1.24–
2.11; OR=2.20, 95% CI=1.04–4.63; OR=4.99, 95%
CI=2.54–9.81 and OR=18.29, 95% CI=2.11–158.24, respec-
tively). Moreover, significantly multiplicative interactions were
observed between COX-2 haplotypes and smoking (Pinterac-
tion=2.65610
-6).
Discussion
In this current study, we conducted a case-control study to
investigate whether three functional polymorphisms in COX-2,
including –1195G.A (rs689466), –765G.C (rs20417), and
587Gly.Arg (rs3218625), interacting with smoking, affect GCA
risk in Chinese Han population. In stratified analysis, the effects of
these three SNPs on GCA risk varied by smoking status.
Table 2. Genotype frequencies of COX-2 SNPs and their
association with GCA risk.
COX-2 genotypes Cases/controls OR (95% CI)
{ FDR-P
{
–1195GRA
GG 69/217 Reference
AG 175/527 1.03 (0.7521.42) 0.847
AA 113/241 1.50 (1.0522.13) 0.038
–765GRC
GG 324/940 Reference
GC 33/45 2.06 (1.2923.29) 0.009
587Gly/Arg
Gly/Gly 327/933 Reference
Gly/Arg 30/52 1.67 (1.0422.66) 0.033
{ORs and 95% CIs were calculated by unconditional logistic regression after
adjusting for sex, age and smoking status.
{P values were modified by the false discovery rate (FDR) correction for multiple
comparisons.
doi:10.1371/journal.pone.0021894.t002
Table 3. Distribution of COX-2 haplotypes and their association with GCA.
Haplotype Controls n = 985 Cases n = 357 OR (95%CI)
{ P value
No. of chromosomes (%) No. of chromosomes (%)
G21195-G2765-G Gly587Arg
A21290-G21195-G2765
913 (46.3) 290 (40.6) Reference
A21195-G2765-G Gly587Arg 960 (48.7) 361 (50.6) 1.19 (0.10–1.43) 0.053
G21195-G2765-AGly587Arg 44 (2.2) 23 (3.2) 1.71 (1.01–2.88) 0.046
A21195-C2765-GGly587Arg 41 (2.1) 33 (4.6) 2.49 (1.54–4.01) 1.896610
-4
A21195-G2765- AGly587Arg 8 (0.4) 7 (1.0) 2.60 (0.93–7.23) 0.068
{ORs and 95% CIs were calculated by unconditional logistic regression after adjusting for sex, age and smoking status.
P for trend test=1.000610
25.
doi:10.1371/journal.pone.0021894.t003
COX-2 SNPs and Gastric Cardia Adenocarcinoma
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between these three SNPs and smoking in GCA development.
This study firstly suggested that the interaction of smoking with the
COX-2 –1195G.A, –765G.C, and 587Gly.Arg significantly
contributed to GCA risk.
It was shown that COX-2 over-expression could increase
proliferation, inhibit apoptosis, and enhance the invasiveness of
cancer cells. Over-expression of COX-2 has been frequently seen
in gastrointestinal malignancies, including pancreas, colon, non-
cardia gastric cancer, and GCA [22,23,24,25]. Interestingly, the
smoking specified carcinogen, nicotine might act through b-
adrenoceptors while NNK through both b-adrenoceptors and a7-
nAChR, and induce COX-2 and its derived PGE2 in gastric
cancer cells [13]. Cigarette smoke condensate could also induce
COX-2 expression by activating nuclear factor kappa B (NF-kB)
[26]. Furthermore, nicotine has been shown to facilitate gastric
tumor angiogenesis and invasion, suggesting heighten expression
of COX-2 induced by smoking might contribute to gastric
carcinogenesis. There was evidence that SNPs altering COX-2
expression and activity have been implicated in risk of smoking-
associated cancers, including lung, pancreatic, and non-cardia
gastric cancer. However, few have done to investigate whether
SNPs in COX-2 affect GCA risk solely or in manner of interaction
with smoking. Additionally, the effect of smoking on COX-2
enzyme was involved not only in the transcriptional expression but
also in the enzymatic activity [13,27,28,29]. Therefore, we
analyzed three functional SNPs, –1195G.A and –765G.Ci n
promoter region and 587Gly.Arg in coding region, in this
current study.
The most significant finding in this study was that the variants of
three functional SNPs identified by our previously studies
interacted with smoking to increase risk of GCA. Of these three
functional SNPs, –1195A-containing or –765C-containing COX-2
promoter displays higher transcriptional activity, supported by
examining the COX-2 expression level of these two variants by
real-time PCR quantitation of COX-2 mRNA in individual
esophageal tissues [16]. Moreover, smoking exposure can rapidly
induce COX-2 expression; hence, the joint effect of the variant
and smoking has been expected to increase COX-2 expression. In
this current study, significantly association between the –1195AA
genotype and increased risk of GCA was only seen among
smokers, and multiplicative interaction was observed between this
variant and smoking, suggesting the cooperation of –1195G.A
and smoking in modulation of GCA risk. Similar result was also
observed for the other functional SNP of –765G.C in the
promoter region, which was consistent with our previously finding
that this SNP interacted with smoking to intensify the risk of
pancreatic cancer. Moreover, the biochemical evidence that the
markedly higher expression of COX-2 drove by the –765C-
containing promoter than the –765G-containing promoter was
only seen in the cells treated with smoke condensate has strongly
supported this current result [17]. Additionally, the variant of
587Gly.Arg in coding region was also found to interact with
smoking exposure to intensified GCA risk, being consistent with
our previous finding that heavy smokers with the 587 Gly/Arg
genotype presented the highest risk for ESCC compared with non-
smokers with the wild-type genotype. Furthermore, biochemical
evidence has suggested that the substitution of Gly to Arg, might
affect COX-2 activity which was examined in the MCF-7 cells by
enzymatic activity assays [18]. Considering that cigarette smoking
also influenced COX-2 enzymatic activity, our result for the
interaction of the 587 Gly.Arg variant with smoking was
biologically plausible. Analysis was also performed on the
haplotypes composing these three functional SNPs in GCA. The
findings that the variant haplotypes was only associated with
smokers’ GCA risk and significant multiplicative interaction was
observed between haplotypes and smoking further supported the
hypothesis that the functional SNPs altering COX-2 expression
and activity interacted with smoking to modulate GCA risk.
In summary, our study highlights the contribution of the
interaction between smoking and functional SNPs in COX-2 to
GCA susceptibility, raising the prospect of research in persona-
lized prevention strategies to smoking-associated GCA.
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-6
A21195-G2765-GGly587Arg 172/524 1.22 (0.95–1.58); 0.124 189/436 1.62 (1.24–2.11); 3.928610
-4
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A21195-C2765-GGly587Arg 11/25 1.58 (0.76–3.29); 0.226 22/16 4.99 (2.54–9.81); 3.240610
-6
A21195-G2765-A Gly587Arg 2/7 0.97 (0.20–4.75); 0.974 5/1 18.29 (2.11–158.24); 0.008
{ORs and 95% CIs were calculated by unconditional logistic regression after adjusting for sex and age.
doi:10.1371/journal.pone.0021894.t005
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